1. Belpomme D, Mathé G, Davies AJS (1977) Clinical significance and prognostic value of the T-B immunological classification of human primary acute lymphoid leukaemias. Lancet 1:555–558.
2. Bernard J, Boiron M, Jacquillat C, Weil M, Najean Y (1966) Un nouvel agent actif dans le traitement des leucémies aiguës: La cytosine arabinoside. Presse Med 74:799–802
3. Florentin I, Kiger N, Bruley-Rosset M, Schulz J, Mathé G (1978) Effect of seven immunomodulators on different types of immune responses in mice. In: Serrou B, Rosenfeld C (eds) Human lymphocyte differntiation: Its application to cancer. Elsevier/North-Holland, Biomedical Press, Amsterdam, pp 299–304
4. Florentin I, Schulz J, Bruley-Rosset M, Kiger N, Mathé G (1980) In vivo immunomo- dulating properties of two synthetic agents: Azimexon and tuftsin. In: Mathé G, Muggia F (eds) Cancer chemo- and immunopharmacology. II. Immunopharmacology, relations and general problems. Springer, Berlin Heidelberg New York
5. Goutner A, Schwarzenberg L, Mathé G (1980) Phase I study of Azimexon in immunodepressed cancer patients. In: Second International Conference: Immunotherapy of cancer, present status of trials in man, Bethesda, xx April 1980